CureVac signs agreement with Sanofi to develop prophylactic vaccine
The agreement was the result of a successful multi-year collaboration in which CureVac met all pre-agreed milestones and acceptance criteria relating to the agreements. Sanofi and CureVac are also part of a positive and ongoing four-year, $33.1 million research collaboration that was co-funded by the Defense Advanced Research Projects Agency.
Under the terms of the commercial license agreement, Sanofi will fund all research, development, manufacturing and commercialization activities for the RNActive vaccine. Sanofi will provide CureVac with an undisclosed upfront payment and have exclusive worldwide marketing rights for RNActive vaccines.
"Sanofi Pasteur's basic objective of finding new vaccine solutions to address patients' needs is furthered by our collaboration with CureVac," Nicolas Burdin, the head of discovery research at Sanofi Pasteur, said. "Accessing CureVac's innovative mRNA technology may allow Sanofi Pasteur to exploit a platform that can be more broadly applicable across indications to develop vaccines, as the RNActive technology is expected to complement conventional technologies."
CureVac will be eligible to receive additional milestone payments up to $205.7 million for achieving multiple clinical, regulatory and commercial milestones, in addition to royalty payments associated with the sale of RNActive vaccines.
"We are very pleased that our RNActive technology platform has reached all significant milestones in this important collaboration with Sanofi Pasteur, the largest company entirely dedicated to vaccines," Ingmar Hoerr, the CEO of CureVac, said. "Our mRNA-based approach shows significant advantages for the development of vaccines, particularly for infectious diseases, such as thermostability and low cost of goods after up-scaling."
CureVac seeks to pioneer the field of RNA-based technology platforms for medical purposes, such as cancer immunotherapies and prophylactic vaccines against infectious diseases.